ATTR Webinar 07232022

Amyloidosis Support Groups webinar on ATTR amyloidosis from July 23, 2022. Led by ASG President Muriel Finkel, featured speakers include:

Frederick Ruberg, MD, Associate Chief, Cardiovascular Medicine, BU Medical Center, Boston, MA
Jignesh K. Patel, MD, PhD, Cedars-Sinai California Heart Center, Beverly Hills, CA
Chafic Karam, MD, Neurologist, Associate Professor of Neurology, University of Pennsylvania, Philadelphia, PA
Michael Maitland, MD, PhD, Sr. Director, Clinical Development, Intellia Therapeutics
Colleen Moffitt, PharmD, MS, US ATTR Medical Director, Alnylam Pharmaceuticals
Gustavo Buchele, MD, PhD, Executive Director, Clinical Development, Ionis Pharmaceuticals
Craig Spolsky, Advocacy & Professional Relations Director, Pfizer, Inc.
Chris Olson, Senior Director, Vyndamax Access & Patient Solutions, Pfizer, Inc.
Jonathan Wall, PhD, Professor, University of Tennessee Graduate School of Medicine, Knoxville, TN
Paula Schmitt, Executive Director, Amyloidosis Support Groups

Chapters
0:00 Welcome and Speaker Introductions
3:05 ATTR Treatment Chart
3:30 Dr. Rick Ruberg, Update in ATTR Amyloidosis Treatments
39:43 Dr. Jignesh Patel, Non-ATTR Specific Therapies
1:08:50 Q&A Session 1: Cardiology focus with Ruberg, Patel
1:22:37 Dr. Chafic Karam, Neuropathy In Amyloid: Symptoms Management
1:52:10 Q&A Session 2 with Karam, Ruberg, Patel
2:10:55 Dr. Michael Maitland, Intellia, CRISPR/CAS9 Gene Editing for Transthyretin (ATTR) Amyloidosis
2:22:53 Colleen Moffit, Alnylam Update
2:30:12 Dr. Gustavo Buchele, AstraZeneca/Ionis TTRansform Update
2:35:49 Craig Spolsky, Chris Olson, Pfizer Update
2:42:35 Dr. Jonathan Wall, AT-01 Diagnostic Imaging Agent for Systemic Amyloidosis
2:58:44 Q&A Session 3
3:12:52 Paula Schmitt, Financial Assistance Update

This webinar video has been edited for content and time. Please note that some questions and subsequent responses by pharmaceutical representatives who participated in this webinar have been deleted from this recording because the responses have not been authorized for post-webinar publication and distribution.